Moffat

Researchers are studying children and young adults aged 1 to 18 years with chronic kidney disease CKD and proteinuria, a condition where the kidneys leak protein into the urine. This study aims to evaluate the long-term safety of finerenone when added to standard treatments called ACE inhibitors or angiotensin receptor blockers ARBs, which are commonly used to control blood pressure and protect kidney function. The research also seeks to understand how well finerenone can reduce protein levels in urine and support kidney health over time. Participants will receive finerenone in doses adjusted by age and body weight, taken orally for up to 18 months alongside their usual ACEI or ARB treatment. The study includes patients who previously took part in a related trial and will follow them for about 19 months, including a one-month follow-up after treatment ends. The research involves one group receiving finerenone openly without placebo or comparison groups. During the study, participants will attend at least 8 to 12 visits depending on their treatment start status. At these visits, doctors will measure vital signs like blood pressure, heart rate, weight, and height perform physical exams collect blood and urine samples to monitor kidney function and protein levels and conduct heart tests using electrocardiograms and echocardiography. Participants and their caregivers will also answer questions about medication use, side effects, and overall well-being. Safety will be closely monitored by tracking any medical problems that arise during the trial.

This observational study collects data from preterm babies with retinopathy of prematurity ROP who are treated with aflibercept Eylea using a paediatric dosing device PDD. ROP affects the retina in premature infants, especially those born before 32 weeks gestation or weighing less than 1.5 kilograms, and may lead to vision problems or blindness if untreated. The study aims to understand how many babies in the UK receive aflibercept with this dosing device and to evaluate if this number is sufficient for future safety studies. Participants are preterm infants diagnosed with ROP who receive aflibercept 0.4 mg via an Eylea prefilled syringe combined with the PICLEO paediatric dosing device. This drug blocks abnormal blood vessel growth in the retina by targeting vascular endothelial growth factor VEGF. Data are collected from the National Neonatal Research Database covering babies born from March 2024 to March 2025 or until April 2027 if more data are needed. Since this is an observational study, no additional visits or tests are required beyond routine care. Researchers will review existing data on participant characteristics such as age, sex, race, maternal factors, clinical conditions, and treatment outcomes. The main outcome measures include the number of babies treated with aflibercept using the PDD and summaries of their clinical and ocular conditions over up to three years after market introduction.

Researchers are investigating whether early atrial fibrillation ablation reduces cardiovascular events in patients with atrial fibrillation who have a high burden of other health problems, measured by a CHA2DS2-VASc score of 4 or more. This is an international, randomized, open trial designed to compare early ablation with usual care to see if it lowers risks of stroke, cardiovascular death, or heart failure events. The study also looks at safety, patient-reported outcomes, and cognitive function in this population. Participants are randomly assigned to one of two groups one group undergoes early atrial fibrillation ablation, specifically pulmonary vein isolation within two months of randomization, while the other group receives usual care following guideline-based treatments tailored to their individual medical needs. All treatments involved are approved therapies. The trial aims to enroll 2312 patients and will continue until a set number of cardiovascular events have occurred, with an estimated average follow-up of about four years. During the study, researchers will monitor cardiovascular complications including death, stroke, and hospitalizations related to heart failure. They will also track serious complications from atrial fibrillation therapy and assess quality of life, heart function, rhythm status, cognitive function, and hospital stays over the follow-up period. Patients will be regularly evaluated for both safety and effectiveness outcomes throughout the study duration.

Researchers are investigating how well the drug VITRAKVI generic name larotrectinib works and how well patients tolerate it in real-world use for those with TRK fusion cancer. This cancer type involves a genetic change called an NTRK gene fusion that can cause tumors to grow. The study includes adults and children with locally advanced or metastatic solid tumors that have this specific gene fusion, reflecting a variety of common and rare cancers. Patients enrolled in this observational study are those for whom their doctors have decided to treat with larotrectinib. Treatments and medical care follow local standard practices without interference from the study. Participants are grouped based on cancer types like gastrointestinal, head and neck, soft tissue sarcoma, CNS, lung, melanoma, pediatric tumors, and others. Data on treatments, other medications, disease changes, and health symptoms will be collected during routine care. Participants will be observed for 24 to 60 months. Researchers will collect information on treatment side effects up to 30 days after treatment ends and monitor responses, disease control, survival, doses, and developmental milestones for up to 8 years. Medical records, including height, weight, neurological assessments, and Tanner stage will be reviewed as part of this long-term observation.